Our Company

our partnering strategy

We are developing therapies that, administered just once, have the potential to transform the lives of people with severe genetic and rare diseases and cancer. Our current platform is just the beginning. We are committed to continuing to develop gene therapy technologies and capabilities that have broad potential beyond the core indications.

We are actively seeking collaborators and licensing opportunities in the U.S. and around the world to explore the therapeutic potential of our technologies in new cell types and diseases.

what we’re looking for

We are actively seeking collaborators, in- and out-licensing opportunities to fully leverage the transformational therapeutic potential of our platforms. Specific areas of interest include:

  • Novel and impactful applications of bluebird’s megaTAL gene editing technology
  • CAR T / TCR immunotherapy targets with highly tumor-specific expression profiles
  • Clinically-relevant CAR T / TCR immunotherapy programs with compelling and comprehensive preclinical POC data
  • Novel technologies which may enhance key features of CAR T / TCR immunotherapies
  • Clinically-relevant viral vector-based gene therapy programs for severe genetic diseases with compelling and comprehensive preclinical POC data
  • Novel technologies which may enhance key features of hematopoietic stem cell-based lentiviral gene therapy

contact us

Are you interested in partnering with bluebird? Please contact us at partner@bluebirdbio.com

our current partners

In March 2013, we teamed up with Celgene Corporation to develop chimeric antigen receptor (CAR) T cell therapies to target and destroy cancer cells. In June 2015, we amended and restated our collaboration to focus on developing product candidates targeting B-cell maturation antigen (BCMA) during a three-year term. BCMA is the first target selected to advance to the clinic under this collaboration. BCMA is a cell surface protein that is expressed in normal plasma cells and in most multiple myeloma cells, but is absent from other normal tissues.We are working in collaboration with Celgene on the initial, lead anti-BCMA product candidate (bb2121), and develop next-generation anti-BCMA product candidates. We will retain sole rights to develop all other chimeric antigen receptor (CAR) T cell programs developed by us under the collaboration, including ongoing undisclosed preclinical programs with opportunities in both solid tumors and hematologic malignancies.

In December 2017, we entered into a strategic research collaboration and licensing agreement with TC BioPharm to discover and develop gamma delta CAR T cell product candidates for cancer immunotherapy.

Under the terms of the agreement, TC BioPharm is responsible for development of all targets through Phase 1/2, at which point we have the exclusive option to assume sole responsibility for further clinical development and commercialization on a global basis.

In June 2016, we entered into a strategic manufacturing agreement with Lonza Houston, Inc., providing for the future commercial production of our Lenti-D™ and LentiGlobin™ drug products.

This agreement follows a successful multi-year clinical manufacturing relationship and provides us with a path to commercial supply including dedicated production suites within Lonza’s state-of-the-art facility. Under this multi-year agreement, Lonza will complete the suite design, construction and validation along with process validation prior to anticipated commercial launch.

In September 2016, we entered into a strategic research and development collaboration and licensing agreement with Medigene AG for T cell receptor (TCR) immunotherapies against four targets. In this partnership, Medigene will be responsible for the generation and delivery of the TCRs using its TCR isolation and characterization platform. Following the collaborative preclinical development, bluebird bio will assume sole responsibility for the clinical development and commercialization of the TCR product candidates and will receive an exclusive license for the intellectual property covering the resulting TCRs.

In December 2016, we entered into a strategic manufacturing agreement with apceth Biopharma for the future European commercial production of our Lenti-D™ product candidate for cerebral adrenoleukodystrophy and our LentiGlobin™ product candidate for transfusion-dependent β-thalassemia.

Under this multi-year agreement, apceth Biopharma will perform clinical manufacturing, process validation activities and commercial manufacturing for LentiGlobin and Lenti-D drug product to support the treatment of European patients with transfusion-dependent beta thalassemia and cerebral adrenoleukodystrophy, respectively. This agreement follows a successful multi-year manufacturing relationship and provides us with European commercial manufacturing capabilities, including dedicated production suites within apceth Biopharma’s state-of-the-art GMP facility.